Understanding the Hidden Costs of Non-PHARMAC Drugs and Their Impact on Healthcare

Access to affordable medication is a cornerstone of effective healthcare systems worldwide. In New Zealand, PHARMAC plays a crucial role by managing the funding and availability of many prescription drugs. Yet, numerous medications fall outside PHARMAC’s coverage. These non-PHARMAC drugs often come with significant hidden costs that affect patients, healthcare providers, and the system as a whole. This article explores these costs, their causes, and the broader impact on healthcare.

What Are Non-PHARMAC Drugs?

PHARMAC is New Zealand’s Pharmaceutical Management Agency responsible for deciding which medicines receive public funding. Drugs not listed on PHARMAC’s schedule are known as non-PHARMAC drugs. These may include:

• New or specialized medications not yet approved for funding

• Drugs for rare or complex conditions

• Brand-name drugs without generic alternatives

• Medications with limited evidence of cost-effectiveness

  
  

Patients needing these drugs often pay the full price or a significant portion out of pocket, which can be costly.

Why Do Non-PHARMAC Drugs Cost More?

Several factors contribute to the higher cost of non-PHARMAC drugs:

Lack of Bulk Purchasing Power

PHARMAC negotiates prices by purchasing medicines in bulk for the entire country. This volume buying power drives prices down. Non-PHARMAC drugs, purchased individually or in smaller quantities, miss out on these discounts.

Limited Competition

Many non-PHARMAC drugs are specialized or newer medications with few or no generic alternatives. Without competition, manufacturers can set higher prices.

Import and Distribution Costs

Some non-PHARMAC drugs are imported or sourced from overseas suppliers, adding shipping, customs, and handling fees. These costs increase the final price for patients.

Administrative and Prescribing Challenges

Doctors may need to apply for special approval or exemptions to prescribe non-PHARMAC drugs. This process can delay treatment and add administrative costs to healthcare providers.

The Impact on Patients

The high cost of non-PHARMAC drugs affects patients in several ways:

Financial Burden

Patients often face large out-of-pocket expenses. For example, a cancer patient requiring a non-PHARMAC chemotherapy drug might pay thousands of dollars monthly. This financial strain can lead to:

• Skipping doses or stopping treatment early

• Choosing less effective but cheaper alternatives

• Increased stress and reduced quality of life

  
  

Inequity in Access

Not all patients can afford non-PHARMAC drugs, creating disparities in treatment access. Those with private insurance or higher incomes have better chances of obtaining these medications, while others may go without.

Health Outcomes

Delays or inability to access effective drugs can worsen health outcomes. For chronic or life-threatening conditions, this can mean faster disease progression or complications.

Effects on Healthcare Providers and the System

Non-PHARMAC drug costs also influence healthcare providers and the broader system:

Increased Administrative Work

Doctors and pharmacists spend time navigating approval processes for non-PHARMAC drugs. This reduces time available for patient care and adds to healthcare costs.

Pressure on Public Hospitals

When patients cannot afford non-PHARMAC drugs privately, they may require more hospital visits or emergency care, increasing pressure on public health services.

Budget Challenges

Hospitals and clinics sometimes cover part of the cost for non-PHARMAC drugs, straining limited budgets and potentially diverting funds from other services.

Examples of Non-PHARMAC Drug Costs

• Orkambi: A cystic fibrosis drug not funded by PHARMAC, costing around NZD 250,000 per patient annually.

• Certain cancer immunotherapies: These can cost tens of thousands per treatment cycle and may not be funded for all eligible patients.

• Rare disease treatments: Medications for conditions like Duchenne muscular dystrophy can exceed NZD 300,000 per year.

  
  

These examples highlight the scale of costs patients and the system face.

Potential Solutions and Strategies

Addressing the hidden costs of non-PHARMAC drugs requires coordinated efforts:

Expanding PHARMAC’s Funding List

Regularly reviewing and adding effective non-PHARMAC drugs to the funded list can improve access and reduce costs.

Encouraging Generic Alternatives

Supporting the development and approval of generic versions can increase competition and lower prices.

Transparent Pricing and Negotiations

Greater transparency in drug pricing and stronger negotiation strategies can help secure better deals for non-PHARMAC drugs.

Patient Assistance Programs

Pharmaceutical companies and charities can offer subsidies or support programs to help patients afford expensive medications.

Streamlining Approval Processes

Simplifying the prescribing and approval process for non-PHARMAC drugs reduces delays and administrative burdens.

What Patients Can Do

Patients facing non-PHARMAC drug costs can take several steps:

• Discuss all treatment options and costs openly with healthcare providers

• Explore eligibility for subsidies or assistance programs

• Consider seeking a second opinion or clinical trials offering access to new drugs

• Connect with patient advocacy groups for support and information

  
  

Looking Ahead

The challenge of non-PHARMAC drug costs is complex but critical. As medical advances continue, more specialized and costly drugs will emerge. Balancing innovation, affordability, and access will require ongoing attention from policymakers, healthcare providers, and communities.

By understanding these hidden costs and their impact, stakeholders can work toward a healthcare system that offers effective treatment to all patients without undue financial hardship.